Location History:
- Greater Noida, IN (2017 - 2019)
- Uttar Pradesh, IN (2023)
Company Filing History:
Years Active: 2017-2023
Title: Innovations of Sandip Middya in the Kynurenine Pathway
Introduction
Sandip Middya is a notable inventor based in Greater Noida, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of inhibitors targeting the kynurenine pathway. With a total of two patents to his name, Middya's work is paving the way for new therapeutic options.
Latest Patents
Middya's latest patents focus on novel inhibitors of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxygenase. These compounds, along with their metabolites and pharmaceutically acceptable salts or prodrugs, are designed to treat diseases resulting from dysregulation of the kynurenine pathway. The compounds act by inhibiting the enzymatic activity or expression of the aforementioned enzymes, providing a promising avenue for therapeutic intervention.
Career Highlights
Middya is currently associated with Curadev Pharma Pvt Ltd, where he continues to innovate and develop new pharmaceutical solutions. His expertise in the kynurenine pathway has positioned him as a key player in the research and development of novel treatments.
Collaborations
Some of his coworkers include Monali Banerjee and Ritesh Shrivastava, who contribute to the collaborative efforts at Curadev Pharma Pvt Ltd.
Conclusion
Sandip Middya's work in developing inhibitors of the kynurenine pathway showcases his commitment to advancing pharmaceutical science. His contributions are expected to have a lasting impact on the treatment of related diseases.